Mycophenolate Mofetil for the Treatment of Resistant Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
ASIDE Gastroenterology · 2025
DOI: 10.71079/aside.gi.03132515 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift ASIDE Gastroenterology, 2025. Verfasst von Natalie Balassiano und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This systematic review evaluates the efficacy and safety of Mycophenolate Mofetil (MMF) for managing treatment‐resistant Inflammatory Bowel Disease (IBD), emphasizing remission rates and adverse effects.
Methods
Observational and controlled trials assessing MMF’s impact on IBD were included, excluding non-English and pediatric studies. Comprehensive searches were conducted in Embase, Medline/PubMed, Scopus, and Web of Science through October 2023. The risk of bias was evaluated using the NIH quality assessment tool, and results were synthesized using a random-effects meta-analysis model.
Results
Twelve studies comprising 446 participants (333 with Crohn’s disease and 113 with ulcerative colitis) were analyzed. The meta-analysis revealed remission rates of 62.2% at 8 weeks and 52.8% at 6 months. Adverse effects occurred in 26.1% of patients, with nausea and vomiting being the most common. Treatment discontinuation due to failure and intolerance was observed in 29.7% and 20% of cases, respectively.
Discussion
The findings suggest that MMF effectively induces remission in IBD patients unresponsive to conventional therapies, although a notable proportion experienced adverse events or treatment failure. Careful patient selection and monitoring are essential.
Conclusion
MMF presents a promising alternative for managing resistant IBD, but its adverse effect profile warrants cautious application. Further research is needed to optimize dosing strategies and assess long-term outcomes in this challenging patient population. These results underscore the potential of MMF as an effective therapeutic option while emphasizing the importance of individualized treatment plans and rigorous clinical monitoring. Future studies should focus on long-term safety and dosing. Additional robust research is required.
Zitieren
APA
Balassiano, N., Tidwell, J., Abdelhalim, O., Abusuliman, M., Nassar, M., Beran, A., Cancarevic, I., & Abosheaishaa, H. (2025). Mycophenolate Mofetil for the Treatment of Resistant Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. ASIDE Gastroenterology. https://doi.org/10.71079/aside.gi.03132515
Vancouver
Balassiano N, Tidwell J, Abdelhalim O, Abusuliman M, Nassar M, Beran A, et al. Mycophenolate Mofetil for the Treatment of Resistant Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. ASIDE Gastroenterology. 2025. doi:10.71079/aside.gi.03132515
BibTeX
@article{Balassiano2025,
author = {Balassiano, Natalie and Tidwell, Jasmine and Abdelhalim, Omar and Abusuliman, Mohammed and Nassar, Mahmoud and Beran, Azizullah and Cancarevic, Ivan and Abosheaishaa, Hazem},
title = {Mycophenolate Mofetil for the Treatment of Resistant Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis},
journal = {ASIDE Gastroenterology},
year = {2025},
doi = {10.71079/aside.gi.03132515}
}
EUVIMED